ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients
View Press Release
April 12, 2014
Abbvie to present late-breaking results from TURQUOISE-II study in chronic hepatitis C patients with cirrhosis at the 2014 International Liver Congress
View Press Release
December 18, 2013
Gilead announces SVR12 rates from three phase III studies evaluating a once-daily fixeddose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients
Abbvie releases first of six phase III results from investigational all-oral, interferon-free, 12- week regimen, showing 96% SVR12 in genotype 1 hepatitis C patients new to therapy
